Abstract 537P
Background
Brain metastases (BM) are a clinical challenge in oncology. Further insight on pathobiology is the basis for new treatment approaches. Recently, S100A9 has been postulated as a novel potential biomarker for therapy resistance to radiotherapy in preclinical BM models. Therefore, we aimed to explore S100A9 levels in a real-life BM patient cohort.
Methods
S100A9 protein expression was measured in the serum of patients treated at the Medical University of Vienna between 2019-2023 using an enzyme-linked immunosorbent assay (ELISA) to correlate its levels with clinicopathological parameters. Sample concentrations below the lower limit of quantification (LOQ) were treated as 50% of LOQ´s concentration and considered as non-quantifiable. Samples with a concentration above the upper limit of quantification were remeasured in dilutions.
Results
80 patients (39% male; 61% female) with BM (n=69) and without BM (n=11) were included in this pre-liminary analysis. Median serum level of S100A9 was 23 pg/mL (IQR 16-97 pg/mL). No difference in median S100A9 levels were observed between patients with BM (23 pg/mL, IQR 16-114) and without BM (23 pg/mL, IQR 15-41) at time of blood sampling (p=0.7). Furthermore, no difference was found in median S100A9 levels in BM patients according to primary tumor’s origin (lung cancer 23 pg/mL vs. breast cancer 16 pg/mL, p=0.6) or radiated versus non-radiated BM (37 pg/mL vs. 23 pg/mL, p=0.3). Median overall survival of patients with quantifiable S100A9 levels were significantly longer than patients with non-quantifiable S100A9 serum levels (HR 2.05; p=0.05).
Conclusions
Based on the results of these pre-liminary data, S100A9 levels did neither correlate with BM diagnosis, primary tumor’s origin nor previously applied radiotherapy. However, detected S100A9 levels correlated with survival analysis in this real-life BM patients. Further studies are currently ongoing to further evaluate S100A9 as a diagnostic and predictive biomarker in larger real-world patient cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A.M. Starzer: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca; Financial Interests, Personal, Other, Travel costs: Pharma Mar, MSD, Lilly. M. Preusser: Financial Interests, Personal, Speaker, Consultant, Advisor: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman Group (GLG, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Servier. A.S. Berghoff: Financial Interests, Personal, Research Funding: Daiichi Sankyo, Roche; Financial Interests, Personal, Advisory Board: Roche Bristol Meyers Squibb, Bristol Meyers Squibb, Merck, Daiichi Sankyo, AstraZeneca, CeCaVa; Financial Interests, Personal, Other, Travel costs: Amgen, AbbVie, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10